Long-lived memory T cells are able to persist in the host in the absence of antigen; however, the mechanism by which they are maintained is not well understood. Recently, a subset of human T cells, stem cell memory T cells (T SCM cells), was shown to be selfrenewing and multipotent, thereby providing a potential reservoir for T cell memory throughout life. However, their in vivo dynamics and homeostasis still remain to be defined due to the lack of suitable animal models. We identified T cells with a T SCM phenotype and stem cell-like properties in nonhuman primates. These cells were the least-differentiated memory subset, were functionally distinct from conventional memory cells, and served as precursors of central memory. Antigen-specific T SCM cells preferentially localized to LNs and were virtually absent from mucosal surfaces. They were generated in the acute phase of viral infection, preferentially survived in comparison with all other memory cells following elimination of antigen, and stably persisted for the long term. Thus, one mechanism for maintenance of long-term T cell memory derives from the unique homeostatic properties of T SCM cells. Vaccination strategies designed to elicit durable cellular immunity should target the generation of T SCM cells.
Introduction
Long-lived memory T cells are able to persist in the host in the absence of antigen (1) . In mice, lymphocytic choriomeningitis virus-specific CD8 + T cells are maintained for life after the acute infection (2) . Similarly, in humans, vaccinia virus-specific T cells can be found for many decades after vaccination (3) . However, it is unclear whether these memory cells are long lived per se, or differentiate regularly from a rarer, long-lived antigen-specific precursor population undergoing slow homeostatic turnover (4) .
Dozens of subsets form the memory T cell compartment (5). Conventionally, antigen-experienced T cells have been divided into central memory (T CM ) cells and effector memory (T EM )
cells, according to their phenotype, function, differentiation history, and anatomical localization (6) . Previously, T CM cells as a whole were thought to exhibit stem cell-like behavior, given their capacity to self-renew and to generate more differentiated progeny in response to multiple stimuli (7) . However, this concept was recently challenged by the discovery of an earlier stage of memory T cell differentiation in humans, termed T stem cell memory (T SCM ) (8) . T SCM cells are precursors of other memory cells including T CM cells, and display enhanced self-renewal capacity; T SCM cells can also generate multiple subsets of memory cells in vitro, and, despite sharing multiple functional attributes with conventional memory cells, they maintain a largely naive-like phenotype, with a core of expressed genes characteristic of naive cells (8) . To date, mouse T SCM cells have been described (9, 10) , but those specific for viral or tumor antigens have not been identified, making their relevance in physiology and pathology elusive. To address these questions in a relevant animal model, we attempted to characterize T SCM cells (either as a bulk population or antigen-specific) in healthy nonhuman primates (NHPs) and during the course of SIV infection. The identification of such a population in the NHPs, the most widely used animal model for HIV infection, is directly relevant to the design of an effective HIV vaccine.
Results and Discussion
Human CD8 + T SCM cells display a largely naive-like phenotype, but express high levels of CD95, CXCR3, CD122, and LFA-1 (8, 11) . In order to characterize the role of T SCM cells in the generation of T cell memory in vivo, we sought to determine whether a similar subset of cells exists in NHPs. In both healthy rhesus macaques (RMs) and pigtail macaques (PTMs), we identified CD95 hi CD8 + T cells in the CD45RA + CCR7 + CD27 + CD28 + IL-7Rα + naive-like compartment ( Figure 1A ). Similarly to those in humans, NHP T SCM cells constitute about 2%-3% of circulating CD8 + T cells (Figure 1B) . We also identified a CD4 + T SCM subset in PBMCs, with a phenotype and frequency similar to CD8 + T SCM cells (Supplemental Figure 1 , A and B; supplemental material available online with this article; doi:10.1172/JCI66327DS1). The NHP model allows a detailed examination of cellular distributions in tissues; we found that CD8 + T SCM cells from healthy RMs are most abundant in LNs, less so in the spleen and bone marrow, and are virtually absent at mucosal surfaces, i.e., the jejunum, the rectum, and the BAL, where only T CM and T EM cells are present ( Figure 1C ). CD4 + T SCM cells displayed a similar distribution in the body, although less skewed toward the LNs (Supplemental Figure 1C) . Thus, T SCM cells have a tropism for secondary lymphoid tissues, with a distribution most similar to naive T (T N ) cells. (Figure 2A ), but not in the LNs, spleen, or BM (Supplemental Figure 2C ). In all sites, T SCM cells were mostly HLA-DR negative. Similar phenotypic data were obtained for CD4 + T SCM cells (Supplemental Figure 1D) .
To assess the cytokine production capability of NHP T SCM cells, we stimulated PBMCs from healthy RMs with staphylococcal enterotoxin B (SEB). Following stimulation, all subsets of memory T cells produced IFN-γ, TNF, and IL-2 ( Figure 2C ). The patterns of cytokine expression show that T SCM cells differ from T CM and T EM cells, with a decreased proportion of cells producing a combination of IL-2 and TNF, but not IFN-γ, and an increased proportion of cells producing IFN-γ and IL-2 or IFN-γ only. Overall, their quality of cytokine production differed from conventional memory T cells ( Figure 2C ). T SCM cells also display attributes of memory in vivo, as proliferating (Ki-67 + ) T SCM cells incorporated BrdU following SIV mac 239 infection in PTMs similarly to conventional T CM and T EM cells (Supplemental Figure 2D) . In contrast, BrdU incorporation by T N cells was negligible.
To further assess whether T SCM cells from healthy RMs constitute discrete, less-differentiated memory cells, we evaluated their multipotency (i.e., to generate other subsets) and self-renewing capability (i.e., to maintain a T SCM phenotype) in response to TCR stimulation in vitro with αCD3/CD28 antibodies ( Figure 2D ). In the proliferating (CFSE-diluted) fraction, T SCM phenotype cells could only be recovered from sort-purified T N or T SCM cells. In addition, T SCM cells were also able to generate cells with a T CM , T EM , and terminal effector T (T TE ) phenotype ( Figure 2D ). Importantly, T CM cells could not generate T SCM cells, but did generate T CM and T EM cells. Together, these data indicate that T SCM cells constitute a discrete memory subset and support the concept that T SCM cells serve as precursors of other memory cells, according to the relationship T SCM →T CM →T EM →T TE .
To determine the dynamics of antigen-specific T cell subsets during a natural infection in vivo, we enumerated SIV-specific CD8 + T cells in RMs using Mamu-A*01 pMHCI multimers presenting SIV-derived Gag CM9 or Tat-TL8 peptides (Supplemental Figure 3A ). Antigen-specific T SCM cells were detected within both CM9-and TL8-specific cells at day 21 after infection, thus demonstrating that they are elicited early ( Figure 3A) . The antigen-specific T SCM cells were not merely "bystander" cells, but displayed evidence of activation (HLA-DR + , CD38 bright ) and proliferation (Ki-67 + ) (Supplemental Figure 3B) . At day 21 after infection, CM9-and TL8-specific CD8 + T cells were dominated by T EM -like cells, while T SCM , T CM , and T TE cells constituted a small proportion of the total response ( Figure 3, A and B) .
The biology of the CM9 and TL8 Mamu-A*01-restricted epitopes is highly divergent. Unlike CM9, which is generally maintained intact throughout the chronic phase of infection, the TL8 uniformly undergoes escape mutation within 4-5 weeks after SIV mac 239 or SIV mac 251 infection in 100% of animals (12) (13) (14) . Tat-TL8 sequence variants do not stimulate TL8-specific T cells due to their reduced capability to bind the pMamu-A*01 class I molecule (12) or to signal through the TCR (14) . Following TL8 escape, there is at least a 10 5 -fold decrease in the relative antigen load of TL8 versus CM9. Using this model, it is thus possible to investigate the relative antigen dependence of the different T cell subsets. As expected, viral escape from TL8-directed CTLs resulted in a dramatic decrease in the frequency of total circulating TL8-specific CD8 + T cells between days 21 and 70-120 after infection (Supplemental Figure 3C ). Conversely, CM9-specific CD8 + T cells were maintained at high levels throughout the course of the infection (Supplemental Figure 3C) . Notably, despite the near-complete elimination of antigen (extremely low levels from residual "archival," unmutated virus may persist) (12), TL8-specific CD8 + T cells did not disappear, but remained detectable beyond day 335 after infection (Supplemental Figure 3C) .
Phenotypic analysis of the TL8-specific population revealed a significant difference in the dynamics of memory subsets in response to viral escape mutation. Indeed, the proportion of TL8-specific T EM cells decreased dramatically in favor of the less differentiated T SCM and T CM cells (Figure 3, A and B) . By day 70 after infection, T SCM cells constituted approximately 25% of the total TL8-specific response ( Figure 3B ). In contrast, memory subset distribution within the CM9-specific CD8 + T cells remained unchanged between days 21 and 70 after infection ( Figure 3B ). Furthermore, as would be expected from a loss of antigen, TL8-specific, but not CM9-specific T SCM and T CM cells, became quiescent (Ki-67 -, HLA-DR -) at day 70 after infection (Supplemental Figure 3B) .
Following antigen loss, TL8-specific T CM and T EM cells underwent considerable attrition (respectively, ~10-and ~100-fold decrease in the absolute count at day 70 versus day 14), while T SCM cells did not ( Figure 3C and Supplemental Figure 3D ). Similarly, CM9-specific T SCM counts did not change over time, while the CM9-specific T CM and T EM cells contracted, albeit at markedly slower rates compared with TL8-specific CD8 + T cells (Supplemental Figure 3D ), reflecting the 1-log decrease in viral load following peak viremia by day 70 after infection (i.e., establishment of the viral set point).
CM9-and TL8-specific subsets, FACS-sorted from a chronically SIV-infected RM, were fully functional as they proliferated following cognate peptide stimulation in vitro (Supplemental Figure 4A) . Importantly, each T cell subset regenerated cells with the same phenotype and simultaneously derived more, not less, differentiated progeny according to the relationship Figure 4B) , thus recapitulating the results depicted in Figure 2D and further demonstrating the multipotency and self-renewing capability of T SCM cells in vitro. The distribution of memory subsets observed at day 70 after infection within both the CM9-and TL8-specific populations was similar in 4 animals at more than 335 days after infection (Supplemental Figure 5A) .
Following escape mutation of the TL8 epitope, the frequency of SIV-specific T cell subsets did not change in the inguinal LNs over time in 2 animals, suggesting that their lymphoid localization is not time dependent (Supplemental Figure 5B) . Moreover, the same cells maintained a stable pattern of localization, as described in Figure 1C , during late chronic infection (Supplemental Figure 5C ). Collectively, these findings indicate that T SCM cells are stable, long-lived memory cells with enhanced survival capacity compared with conventional memory cells when little or no antigen is present.
Freshly isolated CM9-specific T SCM cells were indeed less proapoptotic in vitro than T CM and T EM cells during chronic infection (Supplemental Figure 6, A and B) . Similarly, fewer TL8-specific T SCM cells Antibodies, Mamu-A*01 tetramers, and flow cytometry. Surface and intracellular analysis of protein expression and cytokine production was performed as described (8, 18) . Tetramer staining was conducted at 37°C for 10 minutes. Cells were analyzed and sorted using a modified LSR II and FACSAria II, respectively (BD Biosciences).
Apoptosis studies. Fresh PBMCs were cultured in complete RPMI 1640 medium supplemented with αCD49d and αCD28 antibodies (both at 1 μg/ml; BD Biosciences) at 37°C for 42 hours. Surface phosphatidylserine expression was revealed as described (18) .
Proliferation studies. Cell proliferation was determined by dilution of CFSE (Life Technologies) as described (8) . Labeled cells were stimulated for 6 days with 2 μg/ml CM9 and TL8 peptides in the presence of sorted, CD3 -autologous antigen-presenting cells (1:1 ratio to T cells) or with platebound αCD3 (10 μg/ml; clone FN18) plus soluble αCD28 (1 μg/ml; clone CD28.2) antibodies.
In vivo BrdU labeling. Administration of BrdU (Sigma-Aldrich) and analysis of its incorporation were performed as described (18) .
Gene expression analysis. CD8 + T cell subsets were sorted as depicted in Supplemental Figure 7 . See Supplemental Methods for gene expression quantification procedures.
Statistics. Analyses were performed using Prism (GraphPad Software Inc.), JMP (SAS Institute Inc.), and SPICE (NIAID, NIH) (19) . Nonparametric Wilcoxon rank tests were used to compare distributions. When possible, a paired Student's t test (2 tailed) was used. In some cases, nonparametric 1-way ANOVA (Kruskal-Wallis test) was used to compare 3 or more groups. Distributions shown with pie charts were compared with SPICE. P values were considered significant when less than 0.05.
Study approval. All animal procedures were reviewed and approved by the Institutional Animal Care and Usage Committee of the VRC, the NIAID, the NCI, and Oregon Health and Science University (Portland, Oregon, USA). The anonymous human blood sample ( Figure 1A ) was obtained from the NIH blood bank under institutional review board exemption.
